Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

224
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
224
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

151
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
151
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
Pharmacovigilance01:19

Pharmacovigilance

770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
142

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the impact of required attendance on examination performance and pharmacy student perceptions in an infectious diseases course.

Currents in pharmacy teaching & learning·2025
Same author

Antimicrobial stewardship practices in Guatemala: communication, perceptions, and behaviors regarding antimicrobial prescribing.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2025
Same author

Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2025
Same author

Brexpiprazole: A Balance of Risks and Benefits.

The Senior care pharmacist·2025
Same author

Capivasertib.

Hospital pharmacy·2024
Same author

Measuring Pharmacy Student Engagement in a Pharmacotherapy Course With Required Attendance.

American journal of pharmaceutical education·2024
Same journal

Implementation of a paid apprenticeship-model pharmacy technician training program.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Iodixanol-induced acute generalized exanthematous pustulosis: Cross-reactivity to other iodinated contrast media.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Sonrotoclax.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Bulevirtide Acetate-gmod.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Addressing feedback overload in pharmacy residents.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Development of a psychiatric pharmacy internship program at a children's hospital.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles

Related Experiment Video

Updated: May 31, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.5K

Ceftobiprole: A therapeutic update.

Emily M Hitt1, Dana R Bowers1

  • 1Pharmacotherapy Department, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|January 23, 2025
PubMed
Summary
This summary is machine-generated.

Ceftobiprole, a new fifth-generation cephalosporin, is now FDA-approved for specific infections, including those caused by methicillin-resistant Staphylococcus aureus. It offers a safe and effective option when other treatments are limited.

Keywords:
antibioticbloodstreamceftobiproleinfectionpneumoniaupdate

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.2K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.2K

Related Experiment Videos

Last Updated: May 31, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.5K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.2K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.2K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Antimicrobial resistance is a growing global health concern, necessitating novel therapeutic agents.
  • Methicillin-resistant Staphylococcus aureus (MRSA) infections require targeted treatment strategies.
  • Ceftobiprole represents a new fifth-generation cephalosporin developed to address these challenges.

Purpose of the Study:

  • To review new clinical studies on ceftobiprole compared to existing therapies.
  • To provide evidence supporting the use of ceftobiprole in managing specific infectious diseases.
  • To highlight the recent US Food and Drug Administration (FDA) approval of ceftobiprole.

Main Methods:

  • Analysis of recent clinical trial data comparing ceftobiprole with current antimicrobial therapies.
  • Review of safety and efficacy data for ceftobiprole across multiple indications.
  • Evaluation of post-marketing surveillance and real-world data.

Main Results:

  • Ceftobiprole has demonstrated safety and efficacy in treating bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
  • The drug is approved for three indications in the US following updated clinical study data.
  • Ceftobiprole is effective against methicillin-resistant Staphylococcus aureus (MRSA).

Conclusions:

  • Ceftobiprole is a valuable addition to the therapeutic armamentarium for specific bacterial infections, particularly those caused by MRSA.
  • Its use is recommended when conventional treatment options are limited.
  • Continued monitoring of real-world data is essential to further understand ceftobiprole's long-term efficacy and impact in the US.